The Translational Organoid Resource (TOR) core is committed to streamlining the accessibility, creation, storage, and application of organoids and primary cells sourced from patients and model organisms.
Within the domain of cancer research, TOR produces and examines organoids from various cancer types, such as pancreatic, bladder, prostate, colon, and more, with the intent of employing these as preclinical models across diverse experimental scenarios. In addition, the TOR has also generated human iPSC-derived retinal organoids.
